The Open Rheumatology Journal




ISSN: 1874-3129 ― Volume 13, 2019

Sequential Combination Therapy Leading to Sustained Remission in a Patient with SAPHO Syndrome



C.E Huber1, §, A.G Judex1, §, J Freyschmidt2, S Feuerbach3, J Schölmerich*, 1, U Müller-Ladner1, 4
1 Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
2 Department of Radiology, Zentralkrankenhaus St.-Jürgen-Strasse, Bremen, Germany
3 Department of Radiology, University of Regensburg, Regensburg, Germany
4 Department of Internal Medicine and Rheumatology, Justus-Liebig University Giessen/Kerckhoff Clinic Bad Nauheim, Germany

Abstract

The SAPHO syndrome represents a variety of clinically similar disorders with the key features of hyperostotic bone lesions in combination with chronic pustular skin disease. The respective pathophysiology of bone and joint manifestations in SAPHO syndrome is still a matter of discussion. For example it does not appear to represent reactive arthritis and HLA B27 antigen, with the latter being typically present in patients with spondyloarthopathies. Treatment of SAPHO syndrome is also not well established and consists of various antiinflammatory and antirheumatic drugs. Here, we report a female patient with active SAPHO syndrome suffering from sternal swelling of unknown origin that had been known for 10 years and a 4-year-history of severe lower back pain. Remarkable were also a typical pustulous palmar erythema associated with swelling and decreased motility of both MCP-I joints. Inflammation parameters were high with an ESR 68 mm/1st hour and a CRP of 19.6 mg/l. She was initially treated with rofecoxib and doxycycline, followed by sulfasalazine with only partial clinical response. Thereafter, both articular symptoms as well as cutaneous lesions responded well to a combination therapy with methotrexate and sulfasalazine. Thus, the case illustrates nicely that methotrexate in combination with another DMARD can be successfully applied to patients with long-term active SAPHO syndrome.

Keywords: Case report, combination therapy, doxycycline, methotrexate, rofecoxib, SAPHO, sulfasalazine, treatment..


Article Information


Identifiers and Pagination:

Year: 2009
Volume: 3
First Page: 18
Last Page: 21
Publisher Id: TORJ-3-18
DOI: 10.2174/1874312900903010018

Article History:

Received Date: 30/12/2008
Revision Received Date: 14/1/2009
Acceptance Date: 25/2/2009
Electronic publication date: 27/3/2009
Collection year: 2009

Article Metrics:

CrossRef Citations:
0

Total Statistics:

Full-Text HTML Views: 1690
Abstract HTML Views: 985
PDF Downloads: 269
Total Views/Downloads: 2944

Unique Statistics:

Full-Text HTML Views: 651
Abstract HTML Views: 611
PDF Downloads: 165
Total Views/Downloads: 1427
Geographical View

© Huber et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.


* Address correspondence to this author at the Department of Internal Medicine I, University of Regensburg Medical Center, Franz-Josef-Strauss Allee 11, D-93053 Regensburg, Germany; Tel: +49 941 944 7001; Fax: +49 941944 7002; E-mail: juergen.schoelmerich@klinik.uni-r.de§ These authors contributed equally to this paper.





INTRODUCTION

The SAPHO syndrome represents a variety of clinically similar disorders with the key features of hyperostotic bone lesions, frequently seen on the anterior chest wall, in combination with chronic pustular skin disease [1Chamot AM, Benhamou CL, Kahm MF, Beraneck L, Kaplan G, Prost A. Le syndrome acne pustulose hyperostose osteite (SAPHO): resultats d’une enquete nationale Rev Rheum 1987; 54: 187-96.]. The acronym SAPHO (for synovitis, acne, pustulosis, hyperostosis, and osteitis) was proposed by Chamot et al. after a national survey carried out in France 1986 to evaluate the range of skin, bone and joint manifestations observed. At present, there are over 450 published cases of SAPHO syndrome.

The pathogenesis and pathophysiology of bone and joint manifestations in SAPHO syndrome remain controversial. They do not appear to represent reactive arthritis and HLA B27 antigen, which is typically present in patients with spondyloarthropathies, and is usually lacking. However, in clinical practice, SAPHO syndrome has been associated with spondyloarthropathies, especially in those cases showing sacroiliac involvement and enthesiopathies. Sonozaki et al. have proposed diagnostic criteria for the SAPHO syndrome: pustulosis palmaris et plantaris, tenderness and swelling of the sternocostoclavicular region, or in the absence of swelling, the presence of radiologic signs of hyperostosis [2Sonozaki H, Azuma A, Okai K, et al. Clinical features of 22 cases with "inter-sterno-costo-clavicular ossification": a new rheumatic syndrome? Arch Orthop Trauma Surg 1979; 95: 13-22.]. Technetium bone scintigrams and computed tomographs are considered the most important diagnostic tests. Due to the low number of patients, treatment of SAPHO syndrome is poorly established, it consists usually of antiinflammatory agents such as NSAIDs, and corticosteroids for more severe forms [3Kahn MF. Why the “SAPHO” syndrome? J Rheumatol 1995; 22: 2017-9.]. Case reports have also reported the use of various DMARDs with conflicting results [4Oliveri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome Expert Opin Investig Drugs 2006; 15: 1229-33.].

CASE

A 63-year-old woman was referred to our hospital for evaluation of a sternal swelling of unknown origin that had been known for 10 years. In addition, she had a 4-year-history of severe lower back pain. At time of admission, she complained about chronic pain in the lower back and in both metacarpophalangeal (MCP) I joints. She further reported episodes of loose stools and “allergies” to nonsteroidal antirheumatic drugs. Examination showed a tender swelling of her right sternoclavicular joint and a reduced motility of the complete vertebral column. A pustulous palmar erythema (Fig. 1a) associated with swelling and decreased motility of both MCP-I joints was remarkable. Erythrocyte sedimentation rate was 68 mm/1st hour, the C reactive protein concentration was 19.6 mg/l (< 5). Immunoglobulins A and E were elevated, all other rheumatologic parameters including rheumatoid factor were within the normal range or negative. Conventional X-Rays and computed tomographs showed sternal hyperostotic regions with a ventrodorsal diameter of 3 cm and a transversal diameter of 4 cm (Fig. 2a). Bone scintigrams demonstrated multiple enhanced signal intensities that were consistent with pustulotic arthroosteitis (Fig. 2b). A dermatology referral confirmed that the skin eruptions on palms and hands were a manifestation of SAPHO syndrome. The clinical picture combining hyperostosis of the sternum with palmoplantar pustulosis and spondylitis fulfilled the diagnostic criteria for SAPHO syndrome as outlined above. In addition, colonoscopy revealed aphthous lesions in the ileum with histological signs of chronic inflammation.

Fig (1)

(a) Typical pustulous palmar eruptions at the time of initial presentation (↑). (b) Presentation after 6 weeks doxycyline/8 weeks sulfasalazine therapy .



Fig (2)

(a) Axial CT scan of the sternal region reveals marked hyperostosis and osteitis of the sternum (↑). (b) Technetium-99m bone scintigram shows considerable activity in the sternoclavicular, sternocostal joints and the vertebral column (↑). (c) After 26 months of therapy, overall signal intensities have decreased substantially in the sternal region ().



Fig (3)

Overview over treatment and disease activity. ESR values (1st hour) and concurrent therapy are shown for a 31-month-period.



There are several reports about a possible infectious etiology of the SAPHO syndrome. Edlund and coworkers reported isolation of Propionibacterium acnes, a Gram-positive rod, in a series in 7 of 15 patients from patients with SAPHO syndrome [5Edlund E, Johnsson U, Lidgren L, et al. Palmoplantar pustulosis and sternoclavicular arthro-osteitis Ann Rheum Dis 1988; 47: 809-15.] and Ballare et al. have reported a sustained response to doxycycline therapy in two patients with SAPHO syndrome [6Ballara SC, Siraj QH, Maini RN, Venables PJ. Sustained response to doxycycline therapy in two patients with SAPHO syndrome Arthritis Rheum 1999; 42: 819-21.]. Therefore, we decided to start a combination therapy consisting of rofecoxib 12.5 mg daily with doxycycline 100 mg bid although skin cultures of the palmoplantar lesions were negative for bacteria. Sulfasalazine is recommended for the therapy of many HLA B27 antigen-negative and -positive spondylarthropathies and has shown good results for SAPHO syndrome in uncontrolled reports [7Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases Semin Arthritis Rheum 1999; 29: 159-71.]. Although sulfasalazine as a therapeutic agent in SAPHO syndrome has not been evaluated in controlled clinical trials and as other reports link SAPHO syndrome with chronic inflammatory bowel disease [8Kahn MF, Chamot AM. SAPHO syndrome Rheum Dis Clin North Am 1992; 18: 225-46., 9Dharancy S, Talbodec N, Asselah T, et al. The synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a rare extra-digestive manifestation of Crohn's disease: presentation of one case and review of the literature Gastroenterol Clin Biol 1998; 22: 240-3.], we added sulfasalazine with an initial dose of 500 mg twice a day to the patient’s medication.

The patient was discharged and followed on a regular basis in our outpatient rheumatology clinic for two and a half years. The course of disease and treatment are summarized in Fig. (3). The initial treatment with doxycycline had to be discontinued after 6 weeks due to oral aphthous lesions and the dose of sulfasalazine was increased to a total daily dose of 4.5 g. Over 8 weeks, the back and joint improved markedly, skin eruptions disappeared completely (Fig. 1b) and the erythrocyte sedimentation rate (ESR) returned to 32/1st hour. After 6 months under this therapy, bone scintigrams also improved markedly (Fig. 2c). A clinical and scintigraphic relapse occurred when the patient stopped taking her medication for a three month period between clinical visits. Symptoms ameliorated after starting again with sulfasalazine (Fig. 3). After 19 months, due to increased activity, methotrexate (MTX) was added to the above regimen at a dose of 15 mg weekly (in combination with folate) and sulfasalazine was reduced to 500 mg three times a day. For the next three years, back pain was dramatically reduced, with the exceptions of a flare-up during a urinary tract infection and a mild viral respiratory tract infection. The remaining pain in both MCP-I joints resolved after carpal tunnel surgery.

DISCUSSION

The hallmark of SAPHO syndrome is an inflammatory polytopic arthroosteits, which is characteristically sterile, although infectious agents are suspected as trigger [5Edlund E, Johnsson U, Lidgren L, et al. Palmoplantar pustulosis and sternoclavicular arthro-osteitis Ann Rheum Dis 1988; 47: 809-15., 6Ballara SC, Siraj QH, Maini RN, Venables PJ. Sustained response to doxycycline therapy in two patients with SAPHO syndrome Arthritis Rheum 1999; 42: 819-21.]. There are several reports about a possible infectious etiology of the SAPHO syndrome. Edlund and coworkers reported isolation of Propionibacterium acnes, a Gram-positive rod, in a series in 7 of 15 patients from patients with SAPHO syndrome [7Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases Semin Arthritis Rheum 1999; 29: 159-71.] and Ballare et al. have reported a sustained response to doxycycline therapy in two patients with SAPHO syndrome [8Kahn MF, Chamot AM. SAPHO syndrome Rheum Dis Clin North Am 1992; 18: 225-46.]. The present case demonstrates that combination therapy with an antibiotic and a spondyloarthropathy-approved disease-modifying drug (DMARD), e.g. doxycycline and sulfasalazine, may be a successful approach for the initial therapy of this disease entity. Owing to the rare nature of SAPHO syndrome, sulfasalazine has not yet been evaluated in controlled clinical trials as a therapeutic agent. Nevertheless, Sulfasalazine is recommended for the therapy of many HLA B27 antigen-negative and -positive spondylarthropathies. Other reports link SAPHO syndrome with chronic inflammatory bowel disease [9Dharancy S, Talbodec N, Asselah T, et al. The synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a rare extra-digestive manifestation of Crohn's disease: presentation of one case and review of the literature Gastroenterol Clin Biol 1998; 22: 240-3., 10Perez C, Hidalgo A, Olier J, Otermin I. MR imaging of multifocal spondylodiskitis as the initial manifestations of SAPHO syndrome Am J Roentgenol 1998; 171: 1431-2.], and have shown good results for SAPHO syndrome in uncontrolled reports [11Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al. Characterization of the immune response in the synovitis, acne, hyperostosis, osteitis (SAPHO) syndrome Rheumatology 2008; 47: 1160-7.]. Consistent with promising data of Cabay and coworkers, who reported rapid improvement in a patient with pustulosis plantaris and hyperostosis of the lumbar spine after two months of therapy with MTX (7.5 mg weekly) [12Cabay JE, Marcelis S, Dondelinger RF. Inflammatory spondylodiscitis as a unique radiological manifestation of the SAPHO syndrome J Radiol 1998; 79: 337-40.], MTX facilitated in our case the reduction of the dose of sulfasalazine in a similar manner in long term therapy.

REFERENCES

[1] Chamot AM, Benhamou CL, Kahm MF, Beraneck L, Kaplan G, Prost A. Le syndrome acne pustulose hyperostose osteite (SAPHO): resultats d’une enquete nationale Rev Rheum 1987; 54: 187-96.
[2] Sonozaki H, Azuma A, Okai K, et al. Clinical features of 22 cases with "inter-sterno-costo-clavicular ossification": a new rheumatic syndrome? Arch Orthop Trauma Surg 1979; 95: 13-22.
[3] Kahn MF. Why the “SAPHO” syndrome? J Rheumatol 1995; 22: 2017-9.
[4] Oliveri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome Expert Opin Investig Drugs 2006; 15: 1229-33.
[5] Edlund E, Johnsson U, Lidgren L, et al. Palmoplantar pustulosis and sternoclavicular arthro-osteitis Ann Rheum Dis 1988; 47: 809-15.
[6] Ballara SC, Siraj QH, Maini RN, Venables PJ. Sustained response to doxycycline therapy in two patients with SAPHO syndrome Arthritis Rheum 1999; 42: 819-21.
[7] Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases Semin Arthritis Rheum 1999; 29: 159-71.
[8] Kahn MF, Chamot AM. SAPHO syndrome Rheum Dis Clin North Am 1992; 18: 225-46.
[9] Dharancy S, Talbodec N, Asselah T, et al. The synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a rare extra-digestive manifestation of Crohn's disease: presentation of one case and review of the literature Gastroenterol Clin Biol 1998; 22: 240-3.
[10] Perez C, Hidalgo A, Olier J, Otermin I. MR imaging of multifocal spondylodiskitis as the initial manifestations of SAPHO syndrome Am J Roentgenol 1998; 171: 1431-2.
[11] Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al. Characterization of the immune response in the synovitis, acne, hyperostosis, osteitis (SAPHO) syndrome Rheumatology 2008; 47: 1160-7.
[12] Cabay JE, Marcelis S, Dondelinger RF. Inflammatory spondylodiscitis as a unique radiological manifestation of the SAPHO syndrome J Radiol 1998; 79: 337-40.

Endorsements



"Open access will revolutionize 21st century knowledge work and accelerate the diffusion of ideas and evidence that support just in time learning and the evolution of thinking in a number of disciplines."


Daniel Pesut
(Indiana University School of Nursing, USA)

"It is important that students and researchers from all over the world can have easy access to relevant, high-standard and timely scientific information. This is exactly what Open Access Journals provide and this is the reason why I support this endeavor."


Jacques Descotes
(Centre Antipoison-Centre de Pharmacovigilance, France)

"Publishing research articles is the key for future scientific progress. Open Access publishing is therefore of utmost importance for wider dissemination of information, and will help serving the best interest of the scientific community."


Patrice Talaga
(UCB S.A., Belgium)

"Open access journals are a novel concept in the medical literature. They offer accessible information to a wide variety of individuals, including physicians, medical students, clinical investigators, and the general public. They are an outstanding source of medical and scientific information."


Jeffrey M. Weinberg
(St. Luke's-Roosevelt Hospital Center, USA)

"Open access journals are extremely useful for graduate students, investigators and all other interested persons to read important scientific articles and subscribe scientific journals. Indeed, the research articles span a wide range of area and of high quality. This is specially a must for researchers belonging to institutions with limited library facility and funding to subscribe scientific journals."


Debomoy K. Lahiri
(Indiana University School of Medicine, USA)

"Open access journals represent a major break-through in publishing. They provide easy access to the latest research on a wide variety of issues. Relevant and timely articles are made available in a fraction of the time taken by more conventional publishers. Articles are of uniformly high quality and written by the world's leading authorities."


Robert Looney
(Naval Postgraduate School, USA)

"Open access journals have transformed the way scientific data is published and disseminated: particularly, whilst ensuring a high quality standard and transparency in the editorial process, they have increased the access to the scientific literature by those researchers that have limited library support or that are working on small budgets."


Richard Reithinger
(Westat, USA)

"Not only do open access journals greatly improve the access to high quality information for scientists in the developing world, it also provides extra exposure for our papers."


J. Ferwerda
(University of Oxford, UK)

"Open Access 'Chemistry' Journals allow the dissemination of knowledge at your finger tips without paying for the scientific content."


Sean L. Kitson
(Almac Sciences, Northern Ireland)

"In principle, all scientific journals should have open access, as should be science itself. Open access journals are very helpful for students, researchers and the general public including people from institutions which do not have library or cannot afford to subscribe scientific journals. The articles are high standard and cover a wide area."


Hubert Wolterbeek
(Delft University of Technology, The Netherlands)

"The widest possible diffusion of information is critical for the advancement of science. In this perspective, open access journals are instrumental in fostering researches and achievements."


Alessandro Laviano
(Sapienza - University of Rome, Italy)

"Open access journals are very useful for all scientists as they can have quick information in the different fields of science."


Philippe Hernigou
(Paris University, France)

"There are many scientists who can not afford the rather expensive subscriptions to scientific journals. Open access journals offer a good alternative for free access to good quality scientific information."


Fidel Toldrá
(Instituto de Agroquimica y Tecnologia de Alimentos, Spain)

"Open access journals have become a fundamental tool for students, researchers, patients and the general public. Many people from institutions which do not have library or cannot afford to subscribe scientific journals benefit of them on a daily basis. The articles are among the best and cover most scientific areas."


M. Bendandi
(University Clinic of Navarre, Spain)

"These journals provide researchers with a platform for rapid, open access scientific communication. The articles are of high quality and broad scope."


Peter Chiba
(University of Vienna, Austria)

"Open access journals are probably one of the most important contributions to promote and diffuse science worldwide."


Jaime Sampaio
(University of Trás-os-Montes e Alto Douro, Portugal)

"Open access journals make up a new and rather revolutionary way to scientific publication. This option opens several quite interesting possibilities to disseminate openly and freely new knowledge and even to facilitate interpersonal communication among scientists."


Eduardo A. Castro
(INIFTA, Argentina)

"Open access journals are freely available online throughout the world, for you to read, download, copy, distribute, and use. The articles published in the open access journals are high quality and cover a wide range of fields."


Kenji Hashimoto
(Chiba University, Japan)

"Open Access journals offer an innovative and efficient way of publication for academics and professionals in a wide range of disciplines. The papers published are of high quality after rigorous peer review and they are Indexed in: major international databases. I read Open Access journals to keep abreast of the recent development in my field of study."


Daniel Shek
(Chinese University of Hong Kong, Hong Kong)

"It is a modern trend for publishers to establish open access journals. Researchers, faculty members, and students will be greatly benefited by the new journals of Bentham Science Publishers Ltd. in this category."


Jih Ru Hwu
(National Central University, Taiwan)


SCImago Journal Ranking

SCImago Journal & Country Rank

Browse Contents



Webmaster Contact: info@benthamopen.net
Copyright © 2019 Bentham Open